Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil.

by Fernanda O Demitto, Carolina A S Schmaltz, Flávia M Sant'Anna, María B Arriaga, Bruno B Andrade, Valeria C Rolla
Published 2019-01-01

Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014

by Mayara A. Cardoso, Pedro Emmanuel A. A. do Brasil, Carolina Arana Stanis Schmaltz, Flavia M. Sant’Anna, Valeria C. Rolla
Published 2017-01-01

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.

by Tatiana P da Silva, Carmem B W Giacoia-Gripp, Carolina A Schmaltz, Flavia M Sant Anna, Valeria Rolla, Mariza G Morgado
Published 2013-01-01

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

by Mariana S. Xavier, Anete Trajman, Carolina A. S. Schmaltz, Flavia M. Sant’anna, Ivan R. Maia, David J. Hadad, Pedro Emmanuel A. A. do Brasil, Valeria Rolla
Published 2018-01-01

Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV

by Fernanda O. Demitto, Mariana Araújo-Pereira, Mariana Araújo-Pereira, Mariana Araújo-Pereira, Carolina A. Schmaltz, Flávia M. Sant’Anna, María B. Arriaga, María B. Arriaga, María B. Arriaga, Bruno B. Andrade, Bruno B. Andrade, Bruno B. Andrade, Bruno B. Andrade, Bruno B. Andrade, Bruno B. Andrade, Bruno B. Andrade, Valeria C. Rolla, Valeria C. Rolla
Published 2020-09-01